Fig. 8: Mechanisms at the basis of the antitumoral activity of HSPB8 in melanomas cell lines. | Cell Death & Disease

Fig. 8: Mechanisms at the basis of the antitumoral activity of HSPB8 in melanomas cell lines.

From: HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

Fig. 8

When expressed in melanoma cell lines, HSPB8 favors the unprenylated form of RAS over the prenylated form, inhibiting the RAF/MEK/ERK pathway, and facilitates autophagy. Therefore, HSPB8 exerts an antitumoral activity by inhibiting (i) the epithelial-mesenchymal transition (EMT)-like switching, (ii) migration, and (iii) proliferation. This figure was partly generated using Servier Medical Art templates, provided by Servier, licensed under a Creative Commons Attribution 3.0 Unported License; https://smart.servier.com.

Back to article page